About 3SBio

Sansheng Pharmaceutical (the 'Company' or 'Sansheng Pharmaceutical', together with its subsidiaries collectively referred to as the 'Group') is a leading biotechnology company in the people's Republic of China (the 'PRC'). As a pioneer in the biotechnology industry in China, the Group has rich experience in R & D, production and marketing of biomedical products. The Group's core products include Tabio, Recombinant Human Erythropoietin ('rhEPO') products iBio and Cyber, and Yisaipu Mendi. Tabio is the only commercial recombinant human thrombopoietin ('rhTPO') product in the world. According to IQVIA1, Terbiao's market share in mainland China 2 thrombocytopenia treatment by sales was 72.1 per cent in 2021. With two rhEPO products, the Group has been the market leader in rhEPO in mainland China for two decades, with a total share of 42.4% in 2021. Yisepu is a tumor necrosis factor ('TNF') α inhibitor product, occupying 29.5% of the TNF α market share in mainland China in 2021. According to the China Pharmaceutical Association ('China Pharmaceutical Association'), in 2021, Mandy had a dominant 71.2% market share in mainland China's minoxidil tincture market by sales. The Group has also expanded the field of treatment through internal research and development ('R & D') and a number of external strategic cooperation to increase products. At the same time, the Group develops and produces operations ('CDMO') business through strategic bureau contracts to increase its revenue scale. Since its formal operation in December 2021, the mainland business scale of CDMO has increased rapidly. On December 31, 2021, of the 33 products under research actively developed by the Group, 26 were developed as innovative drugs in mainland China. Among the 33 products under research, 18 were monoclonal antibodies ('monoclonal antibodies') or bispecific antibodies, seven were other biological products and eight were small molecular drugs. The Group has ten oncology products in progress; 16 products in progress targeting autoimmune diseases (including rheumatoid arthritis ('RA'), and other diseases, including obstinate gout and eye diseases (such as age-related macular degeneration ('AMD')); six nephrology products in progress; and one dermatology product in progress. The industry in which the Group operates is very attractive. Biotechnology has brought about great changes in the pharmaceutical industry by meeting unmet medical needs and providing innovative treatments for a wide range of human diseases. In mainland China, the biopharmaceutical industry is strongly supported by the government and recognized by the State Council as an important strategic emerging industry. Strong government support and the growing adoption of biopharmaceutical products by doctors in mainland China have contributed to the strong growth of the industry. The Group is expanding around the world. Outside the mainland of China, Terbio has been approved by nine countries; iBio has been approved by 23 countries; and Yisep has been approved by 15 countries. In the long run, the Group's goal is to market its products in developed countries. The Group also cooperates with international partners to develop and market the Group's products under research, such as pegsiticase and anti-programmed death receptor 1 ('PD-1') McAbs. The Group aims to focus on research and development to provide innovative treatments for patients in mainland China and around the world. As at 31 December 2021, the Group has operating facilities in Shenyang, Shanghai, Hangzhou and Shenzhen (all located in mainland China) and Cuomo in Italy with a staff of 5292. The Group's pharmaceutical products are promoted and sold in all provinces, autonomous regions and municipalities directly under the Central Government in mainland China and in a number of overseas countries and regions. For the year ended 31 December 2021 (the 'reporting period'), the Group's national distribution network sold the Group's products to nearly 9000 hospitals and medical institutions in mainland China.